Drug Profile
Research programme: amyloid precursor protein secretase inhibitors - Merck & Co/Wyeth
Alternative Names: Gamma secretase inhibitors - ArQule/WyethLatest Information Update: 20 Jan 2020
Price :
$50
*
At a glance
- Originator ArQule
- Developer Merck & Co; Pfizer; Wyeth
- Class Small molecules
- Mechanism of Action Amyloid precursor protein secretase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Female genital diseases
Most Recent Events
- 16 Jan 2020 ArQule has been acquired and merged into Merck & Co
- 16 Oct 2009 Wyeth has been acquired by Pfizer
- 31 May 2009 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route)